Immunocore Holdings PLC
IMCR32.990USD
0.000
Horário de mercado （ET）Cotações atrasadas em 15 min
1.66BValor de mercado
PerdaP/L TTM
Mais detalhes de Immunocore Holdings PLC Empresa
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Informações da empresa
Código da empresaIMCR
Nome da EmpresaImmunocore Holdings PLC
Data de listagemFeb 05, 2021
CEODr. Bahija Jallal, Ph.D.
Número de funcionários493
Tipo de títulosDepository Receipt
Fim do ano fiscalFeb 05
Endereço92 Park Drive Milton Park
CidadeABINGDON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited Kingdom
Código postalOX14 4RY
Telefone441235438600
Sitehttps://www.immunocore.com/
Código da empresaIMCR
Data de listagemFeb 05, 2021
CEODr. Bahija Jallal, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Tipos de investidores
Investidores
Proporção
Investment Advisor
41.30%
Investment Advisor/Hedge Fund
26.52%
Hedge Fund
22.94%
Corporation
5.15%
Private Equity
3.16%
Research Firm
2.66%
Pension Fund
0.42%
Bank and Trust
0.25%
Venture Capital
0.04%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
292
50.72M
102.46%
-9.05M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
2023Q2
236
43.68M
94.12%
-435.38K
2023Q1
218
40.62M
88.44%
-3.40M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Investment Management, Inc.
7.05M
14.25%
+351.61K
+5.25%
Mar 31, 2025
Wellington Management Company, LLP
6.13M
12.39%
-485.33K
-7.33%
Mar 31, 2025
RTW Investments L.P.
4.87M
9.84%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
9.71%
+23.88K
+0.50%
Mar 31, 2025
PRIMECAP Management Company
2.68M
5.41%
+10.10K
+0.38%
Mar 31, 2025
Eli Lilly Vostok SA Geneva
2.55M
5.15%
--
--
Mar 21, 2025
Baker Bros. Advisors LP
2.32M
4.69%
+807.34K
+53.28%
Mar 31, 2025
Tang Capital Management, LLC
1.92M
3.87%
+360.11K
+23.15%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.89M
3.81%
-299.59K
-13.70%
Mar 31, 2025
Kynam Capital Management LP
1.70M
3.43%
+470.00K
+38.35%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Products ETF
1.7%
Tema Oncology ETF
1.18%
ALPS Medical Breakthroughs ETF
1.07%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.1%
iShares Intl Small Cap Equity Factor ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Ver Mais
Virtus LifeSci Biotech Products ETF
Proporção1.7%
Tema Oncology ETF
Proporção1.18%
ALPS Medical Breakthroughs ETF
Proporção1.07%
Invesco Nasdaq Biotechnology ETF
Proporção0.14%
ProShares Ultra Nasdaq Biotechnology
Proporção0.14%
SPDR S&P International Small Cap ETF
Proporção0.12%
iShares Biotechnology ETF
Proporção0.1%
iShares Intl Small Cap Equity Factor ETF
Proporção0.09%
Fidelity Nasdaq Composite Index ETF
Proporção0.01%
SPDR Portfolio Developed World ex-US ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
